Abstract: Disclosed is a secret-key provisioning (SKP) method and device based on an optical line terminal (OLT), which can generate an SKP queue according to key requests received; generate at least one secret-key according to the SKP queue; and store the at least one secret-key in key pools (KPs) of corresponding ONUS. A non-transitory computer-readable storage medium is also disclosed.

Abstract: The present disclosure provides a semiconductor structure and a manufacturing method thereof. The semiconductor structure includes a substrate, a word line, and at least two dielectric layers. The word line is arranged in the substrate; the at least two dielectric layers are located between the word line and the substrate and have different dielectric constants.

Abstract: Disclosed is a method for allocating QKD network resources, which includes the following steps: obtaining a network structure of a QKD network, and constructing a key topology according to distributions condition of quantum key resources in the QKD network; in response to arrival of a service requiring encryption, judging whether the encrypted service is delay sensitive; when the service is delay sensitive, distributing quantum key resources to the service according to the key topology of the QKD network; and when the service is not delay sensitive, distributing quantum key resources to the service according to the network structure of the QKD network. Moreover, the present disclosure also provides a device for allocating QKD network resources and a non-transitory computer-readable storage medium.

Abstract: Disclosed is a method for allocating QKD network resources, which includes the following steps: obtaining a network structure of a QKD network, and constructing a key topology according to distributions condition of quantum key resources in the QKD network; in response to arrival of a service requiring encryption, judging whether the encrypted service is delay sensitive; when the service is delay sensitive, distributing quantum key resources to the service according to the key topology of the QKD network; and when the service is not delay sensitive, distributing quantum key resources to the service according to the network structure of the QKD network. Moreover, the present disclosure also provides a device for allocating QKD network resources and a non-transitory computer-readable storage medium.

Abstract: Disclosed is a secret-key provisioning (SKP) method and device based on an optical line terminal (OLT), which can generate an SKP queue according to key requests received; generate at least one secret-key according to the SKP queue; and store the at least one secret-key in key pools (KPs) of corresponding ONUS. A non-transitory computer-readable storage medium is also disclosed.

Abstract: A Global Concurrent Optimization (GCO) method, device and system for Label Switching Path (LSP) are provided. The method comprises that: a Path Calculate Element (PCE) calculates the path of each LSP of a set of LSPs in a network, groups all LSPs, and performs a sequencing operation to obtain the setup and/or deleting order of the each LSP in a group to which the each LSP belongs, wherein the each LSP belongs to one group; and the PCE transmits a path calculation response message to a Path Calculation Client (PCC), wherein the path calculation response message carries the path calculation result of the each LSP of the set of the LSPs, the grouping information of the each LSP and the setup and/or deleting order of the each LSP in the group to which the each LSP belongs. According to the disclosure, the optimization/re-optimization efficiency is provided.

Abstract: Medicinal composition containing ginseng secondary glycosides, its preparation method and application. The present composition contains mainly, as active ingredients, the ginsenoside with protopanoxadiol as aglucone (ginsenoside Rg3) and the ginsenoside with protopanoxatriol as aglucone (ginsenoside Rg2 and ginsenoside Rh1). It is prepared from the ginseng genus of plants through extracting, acid hydrolyzing and using macroreticular resin to separate, purify and concentrate. It is useful in the manufacture of medicaments for treating CHD, angina pectoris, myocardial ischemia, hemorrhagic shock, heart failure, and arrhythmia.

Abstract: Medicinal composition containing ginseng secondary glycosides, its preparation method and application. The present composition contains mainly, as active ingredients, the ginsenoside with protopanoxadiol as aglucone (ginsenoside Rg3) and the ginsenoside with protopanoxatriol as aglucone (ginsenoside Rg2 and ginsenoside Rh1). It is prepared from the ginseng genus of plants through extracting, acid hydrolyzing and using macroreticular resin to separate, purify and concentrate. It is useful in the manufacture of medicaments for treating CHD, angina pectoris, myocardial ischemia, hemorrhagic shock, heart failure, and arrhythmia.

Abstract: This invention relates to salts of sulfodehydroabietic acid with bismuth or zinc, a kind of new salt useful in treating digestive canal ulcer, acute & chronic gastritis, and erosive gastritis etc., as well as its preparation and use. Said salts can be represented by formula (1), wherein R is Bi(OH)++ or Zn++, 2Bio+, 1/2ZnH, n=0–10. The preparation method comprises following steps: (a) sequentially treating the industrial abietic acid calcium salt with acid, base and extracting with organic solvent to give abietic acid with less isomer; (b) reacting said abietic acid with Pd/C to provide dehydroabietic acid, then converting it to pure sulphonic product, namely sulfodehydroabietic acid, via sulphonation and recrystallization; (c) by use of neutralization or salt displacement reaction to convert the sulphonic product of zinc or bismuth salts of sulfodehydroabietic acid. The resultant salts can used to prepare medicine for treating digestive canal ulcer and gastritis.

Abstract: This invention relates to salts of sulfodehydroabietic acid with bismuth or zinc, a kind of new salt useful in treating digestive canal ulcer, acute & chronic gastritis, and erosive gastritis etc., as well as its preparation and use. Said salts can be represented by formula (1), wherein R is Bi(OH)++ or Zn++, 2Bio+, 1/2ZnH, n=0-10. The preparation method comprises following steps: (a) sequentially treating the industrial abietic acid calcium salt with acid, base and extracting with organic solvent to give abietic acid with less isomer; (b) reacting said abietic acid with Pd/C to provide dehydroabietic acid, then converting it to pure sulphonic product, namely sulfodehydroabietic acid, via sulphonation and recrystallization; (c) by use of neutralization or salt displacement reaction to convert the sulphonic product of zinc or bismuth salts of sulfodehydroabietic acid. The resultant salts can used to prepare medicine for treating digestive canal ulcer and gastritis.